Rheumatoid Arthritis and Ankylosing SpondylitisCorporate deck (page 12):
"Lead indication: osteoarthritis (OA), to be broadened to include rheumatoid arthritis, ankylosing spondylitis, and other acute and chronic pain indications"
Officially additional indications beyond osteoarthritis in the deck. They didn't say how they are going to do this, but the market cap surely went up.
ATB-346 is not just an anti-inflammatory with the best GI safety on the market, it's officially a GI safe anti-inflammatory for inflammatory diseases. Comes with the #1 scientist in the field in the world and is totally derisked with high quality Phase 2a and 2b trials with high statistical significance proving H2S concept that a slam dunk in Phase 3 trials is pretty much guaranteed.
ATB-346 prior market cap: osteoarthritis
ATB-346 new market cap: osteoarthritis, rheumatoid arthritis, ankylosing spondylitis
Broadening indications for ATB-346 could yield better and more timely returns than ATB-352.
This is going to be very exciting! GLTA